



ASX Release
27 October 2022

DIRECTOR APPOINTMENT – Mr Rod North

- **Mr North to join Compumedics Board as a non-executive director**
- **Mr North brings significant financial services and company analysis experience to the Board and will strengthen the interface with current and future shareholders**
- **Mr North brings significant corporate analysis and financial management skills to the board**

Compumedics Limited (ASX: CMP) (“Compumedics”) is pleased to announce that its current Board of Directors has unanimously agreed to the appointment of Mr. Rod North as a Director of the Company, effective immediately, subject to shareholder approval at the Company’s next General Meeting.

Rod North has been working in the financial services & corporate sector for 30 years, having held leading roles in share broking, investment and funds management and provided investor relations, media & PR services to a large range of ASX listed companies over the past 17 years. He has extensive experience in company analysis and financial management. He has served on a number of investment committees in funds management. He has also acted in high-level corporate advisory roles to private and public companies at senior executive and board level, advising on capital raisings, communication and investor relations strategies.

“We are delighted to have Rod join the Board,” said Dr. David Burton, Executive Chairman and CEO at Compumedics. “He is a very experienced financial services executive who will bring considerable strategic and corporate experience to the Compumedics Board.”

“Rod has extensive experience in financial services, broking and funds management, which are key to Compumedics on-going future success, both locally and in our main global markets.”

Rod joins the board at a very important time with key opportunities not only for the core business but also as it relates to breakout business opportunities including MEG and Somfit projects.” said Dr Burton. “Rod’s contact networks, broking, corporate analysis and financial management in relation to capital markets can potentially contribute to Compumedics value moving forward.”

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture, and commercialisation of diagnostics technology for the sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns US based Neuroscan, and Germany based DWL Elektronische GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: + 61 3 8420 7300
F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors